First-in-Human Experience With 177Lu-DOTAGA.(SA.FAPi)2 Therapy in an Uncommon Case of Aggressive Medullary Thyroid Carcinoma Clinically Mimicking as Anaplastic Thyroid Cancer

  • Clin Nucl Med. 2022 Jun 1;47(6):e444-e445. doi: 10.1097/RLU.0000000000004164.
Sanjana Ballal  1 ,  Madhav Prasad Yadav  1 ,  Euy Sung Moon  2 ,  Frank Rösch  2 ,  Sreedharan Thankarajan ArunRaj  1 ,  Shipra Agarwal  3 ,  Madhavi Tripathi  1 ,  Ranjit Kumar Sahoo  4 ,  Chandrasekhar Bal  1
Affiliations
  • 1. From the Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • 2. Department of Chemistry, TRIGA, Johannes Gutenberg University, Mainz, Germany.
  • 3. Departments of Pathology.
  • 4. Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
PMID: 35507435 DOI: 10.1097/RLU.0000000000004164
Abstract

A 56-year-old man was diagnosed with Calcitonin negative, plasma chromogranin A-positive, immunohistochemistry-negative, high-grade MTC (medullary thyroid Cancer) behaving clinically like anaplastic thyroid Cancer and presented with progressive disease after conventional therapies. A theranostic approach of 68Ga-DOTA.SA.FAPi-guided 177Lu-DOTAGA.(SA.FAPi)2 radionuclide therapy was administered on compassionate grounds as per the Declaration of Helsinki because known standard lines of treatment were ineffective. Treatment with a single cycle of 1.65 GBq 177Lu-DOTAGA.(SA.FAPi)2 demonstrated a sustainable reduction in the neck mass with significant improvement in the quality of life of the patient. 177Lu-DOTAGA.(SA.FAPi)2 is a potential theranostic option for high-grade MTC refractory to standard therapeutic options.

Products